Cambridge Healthtech Institute’s 7th Annual

Cell Therapy Manufacturing

Scaling and Industrializing Cell-Based Therapies

August 26-27, 2020

 

CHI’s Cell Therapy Manufacturing meeting examines the practical challenges in manufacturing autologous and allogenic cell therapies at scale, with dedicated sessions on cell processing, scalability, next-generation production technologies, automation, closed systems, supply chain, and facility design. The meeting will feature extensive sessions on autologous and allogeneic production platforms, including CAR Ts, NK cells, TCRs, TILs, and IPSCs at scale.

Preliminary Agenda

FUTURE OF CELL THERAPY MANUFACTURING

Latest Advances in Cell Therapy Manufacturing

Knut Niss, PhD, CTO, Mustang Bio

The Cell and Gene Therapy Manufacturing: Forecasting the Next Decade

Michael Jacobson, PhD, Managing Partner, Cambridge Biostrategy Associates

Talk Title to be Announced

Sadik Kassim, PhD, CTO, Vor Biopharma

SCALE-UP, PROCESS DEVELOPMENT

Scale-Up Strategies and Process Optimization for Cell Therapies

Kathleen Vermeersch, JnJ

Process Development: Lessons Learned from Virus-Specific T Cells

Adrian Gee, PhD, Professor, Pediatrics-Hem-Onc Cell & Gene, Baylor College of Medicine

Bioprocess Challenges for Regulatory T Cell Production

James Piret, PhD, Professor, Michael Smith Laboratories & Department of Chemical and Biological Engineering, University of British Columbia

AUTOMATION AND SUPPLY CHAIN

Advances in Automation and Robotics

Fabio Fachin, PhD, Head, Cell Therapy Engineering and Automation, Takeda

Operations and Logistics of Running Academic Multicenter Cellular Therapy Clinical Trials

Patrick J. Hanley, PhD, Laboratory Facility Director, Cellular Therapy and Stem Cell Processing, Program for Cell Enhancement and Technologies for Immunotherapy, Division of Blood and Marrow Transplantation, Children’s National Health System

Supply Chain for CAR T Therapies

Alan Smith, Executive Vice President, Technical Development, Bellicum

Scaling Up the Manufacture of Antigen-Specific T Cells

Stéphanie Val, PhD, Staff Scientist, Process Development, Cellular Therapy Laboratory Center for Cancer and Immunology Research, Children's National Hospital




For more details on the conference, please contact:
Daniel Barry
Senior Conference Director
Cambridge Healthtech Institute

Phone: (+1) 781-247-6266
Email: dbarry@healthtech.com

 

For partnering and sponsorship information, please contact:

Companies A-K
Sherry Johnson
Senior Manager, Business Development
Cambridge Healthtech Institute
Phone: (+1) 781-972-1359
Email: sjohnson@healthtech.com

Companies L-Z
Carolyn Cooke
Manager, Business Development
Cambridge Healthtech Institute
Phone: (+1) 781-972-5412
Email: ccooke@healthtech.com



Premier Sponsors:

Fujifilm-Diosynth-Logo

NanotemperTechnologies

Samsung_Biologics

UnchainedLabs
Vironova